1 / 28

Asthma Management In Children Norzila Mohamed Zainudin

Asthma Management In Children Norzila Mohamed Zainudin Consultant Paediatrician & Paediatric Chest Physician Paediatric Institute Hospital Kuala Lumpur. 9 th May 2004. The International Study of Asthma and Allergies in Childhood (ISSAC) Lancet 1998; 351: 1225 - 32.

stacia
Download Presentation

Asthma Management In Children Norzila Mohamed Zainudin

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Asthma Management In Children Norzila Mohamed Zainudin Consultant Paediatrician & Paediatric Chest Physician Paediatric Institute Hospital Kuala Lumpur 9th May 2004

  2. The International Study of Asthma and Allergies in Childhood (ISSAC) Lancet 1998; 351: 1225 - 32

  3. Commonest chronic disease of increasing prevalence • of childhood asthma • Widespread reporting • Prevalence in Malaysia –ISAAC study –10-12% • A difficult disease to diagnose in early childhood • Need to differentiate between episodic wheeze and asthma • Compounded by relatively small diameter of conducting airways in first 4 years of postnatal development • Frequent respiratory tract infections • Under treated base on the AIRIAP study

  4. Pathogenesis • Airway Inflammation • Epithelial damage • Subepithelial basement membrane thickening • Increased vascularization • Myofibrobalst proliferation • Hypertrophy and hyperplasia of smooth muscle

  5. Airway Remodelling • Relationship between airway remodelling • and pathogenesis of asthma remains unclear • May occur early in childhood • Preceeds onset of symptoms • Growing evidence that the loss of • lung function is determined in early childhood

  6. Airway remodelling • Due to chronic inflammation • Epithelium as pro-inflammatory players • Epithelium undergone remodelling in response • to repeated cycles of inflammation and damage • Epithelial fragility • Smooth muscle cells to inflammatory network • playing central role by exposing cell surface • and adhesion molecules producing cytokine • Smooth muscle may de-differentiate and interchange between • Airway myofibroblast and smooth muscle

  7. Martinez • 1246 infants • Children with persistent wheezing • Loss of lung function by 6 years old • Compared to non-wheezers or early transient wheezers • Irreversible damage occurs by 9 years old

  8. Diagnosis History Physical Investigations

  9. History • Wheezing • Chronic cough • Nocturnal exacerbations • Shortness of breath • Chest tightness • Limitation of physical activities • Parental history of atopy • Past history of eczema/rhinitis

  10. Physical • Height – weight • Chest-hyperinflation • Auscultation • Eczema at flexural areas • Nose-nasal turbinate

  11. Investigation • Demonstrate the reversibility of bronchial obstruction • Administer pre/post B2 agonist • FEV-15% increase or 20 % increase in PEF Formula: Post-Pre B2 X 100 % B2

  12. Intermittent Symptoms less than once a week Brief exacerbations Nocturnal symptoms more than twice a month FEV1 or PEF >80 predicted PEF or FEV1 variability <20% Mild Persistent Symptoms more than once a week but less than once a day Exacerbations may affect activity and sleep Nocturnal symptoms more than twice a month FEV1 or PEF > 80% PEF or FEV1 variability 20-30% Classification of asthma severity by clinical features before treatment Global Initiative of Asthma (GINA)

  13. Moderate Persistent Symptoms daily Exacerbations may affect activity and sleep Nocturnal symptoms more than once a week Daily use of inhaled short acting B2 agonist FEV1 or PEF 60-80% predicted PEF or FEV1 variability >30% Severe Persistent Symptoms daily Frequent exacerbations Frequent nocturnal asthma symptoms Limitation of physical activities FEV1 or PEF <60% PEF or FEV1 variability >30%

  14. Asthma Management • Educating patients to develop partnership • Assessing and monitoring of asthma severity using • measurements of symptoms and lung function • Avoiding exposure to risk factors • Establish medication plan • Establish long term asthma management exacerbations • Establishing individual plan • Regular follow-up care GINA 2002

  15. Pharmacological approach to asthma management

  16. Prevent Bronchoconstriction Control Inflammation Clinical control

  17. Spoilt for choices

  18. Guideline recommend adding LABA to ICS GINA guidelines: recommended medications in children Level of severity Daily controller medications Other treatment options Step 1 Intermittent asthma None necessary Step 2 Mild persistent asthma Sustained-release theophylline, OR cromone, OR leukotriene modifier ICS (100–400mg BUD or equivalent) Step 3 Moderate persistent asthma ICS (<800 mg BUD or equivalent) + LABA or sustained-release theophylline or leukotriene modifier OR ICS (>800 mg BUD or equivalent) ICS (400–800 mg BUD or equivalent) Step 4 Severe persistent asthma ICS (>800 mg BUD or equivalent) + one or more of the following, if needed: LABA or sustained-release theophylline, leukotriene modifier or oral corticosteroid Rapid-acting inhaled b2-agonist should be taken as required at all steps BUD, budesonide; ICS, inhaled corticosteroid; LABA, long-acting b2-agonist GINA 2002

  19. Guideline recommend adding LABA to ICS GINA guidelines: recommended medications in children Level of severity Daily controller medications Other treatment options Step 1 Intermittent asthma None necessary Step 2 Mild persistent asthma Sustained-release theophylline, OR cromone, OR leukotriene modifier ICS (100–400mg BUD or equivalent) Step 3 Moderate persistent asthma ICS (<800 mg BUD or equivalent) + LABA or sustained-release theophylline or leukotriene modifier OR ICS (>800 mg BUD or equivalent) ICS (400–800 mg BUD or equivalent) Combination therapy Step 4 Severe persistent asthma ICS (>800 mg BUD or equivalent) + one or more of the following, if needed: LABA or sustained-release theophylline, leukotriene modifier or oral corticosteroid Combination therapy Rapid-acting inhaled b2-agonist should be taken as required at all steps BUD, budesonide; ICS, inhaled corticosteroid; LABA, long-acting b2-agonist GINA 2002

  20. Montelukast (7%) ORAL (45%) Ketotifen (38%) Cromones (5%) INHALED (55%) Corticosteroids (50%) n TREATMENT PREFERENCE FOR ASTHMA PROPHYLAXIS IN CHILDREN UNDER 5 YEARS Chan PWK, Norzila MZ. Med J Malaysia 2003

  21. PERCEPTION OF INHALED CORTICOSTEROIDS AMONG MALAYSIAN PARENTS % parents Chan PWK. J Pediatr Child Health; 46: 522

  22. Inhaler Devices Recommended for Different Ages for Home Therapy • Children aged 0-6 years • Metered dose inhaler + spacer with facemask • Children aged > 6 years • Metered dose inhaler + spacer with facemask • Dry powder inhaler • Breath actuated device (> 8 years)

  23. Availability of CFC Free inhalers HFA-MDI No –ozone depleting effect Reduced global warming Smoother dose delivery Improve dose uniformity No shaking required before inhalation

  24. Thank You

  25. META-ANALYSIS OF LINEAR GROWTH IN CHILDREN AND INHALED CORTICOSTEROIDS Reduction in linear growth 1.51 cm/yr BDP 0.43 cm/yr FP Evidence available for less than 54 weeks of treatment Sharek PJ, Bergman DA. Pediatrics 2000; 106: e8 - 15

  26. Budesonide Nedocromil Placebo CAMP STUDY:Standing-height velocity1041 children aged 5 - 12 years cm/year • Reduction of growth velocity • most evident during • 1st year of treatment • At 4 - 6 years of treatment • No difference in • growth velocity • bone age • bone density • projected final height N Eng J Med 2000;343: 1054 - 63 Years

  27. LONG TERM GROWTH AND INHALED CORTICOSTEROIDS Agertoft L, Pedersen S. Effect of long term treatment with inhaled budesonide on adult height in children with asthma. N Eng J Med 2000; 343: 1064 - 9

  28. Summary Diagnosis Classification of severity New asthma medications Asthma Education Steroid phobia

More Related